DrugMapper


Trade Names:	ADALAT ADALAT CC AFEDITAB CR NIFEDIPINE PROCARDIA PROCARDIA XL
Synonyms:	Adalat Adalat a.r. Adalat cc Adalate lp Adalat ic Adalat la 20 Adalat la 30 Adalat la 60 Adalat ret Adanif xl Adipine mr 10 Adipine mr 20 Adipine xl Afeditab cr Angiopine 10 Angiopine 40 la Angiopine 5 Angiopine mr 10 Angiopine mr 20 BAY A 1040 BAY-A-1040 Calanif Calchan mr 10 Calchan mr 20 Calcilat Cardilate mr Coracten Coracten sr Coracten xl Coroday mr Fortipine la40 Genalat 10 ret Genalat 20 ret Hypolar ret 10 Hypolar ret 20 Hypolar xl 30 Kentipine Kentipine mr 10 Kentipine mr 20 Neozipine xl Nifedipine Nifedipine hydrochloride Nifedipine slow release Nifedipinum Nifedipress mr 10 Nifedipress mr 20 Nifedotard 20 mr Nifelease Nifensar xl Nife-wolff Nifopress mr Nifopress ret Nimodrel mr 10 Nimodrel mr 20 Nimodrel xl Nivaten ret NSC-757242 Procardia Procardia xl Slofedipine xl 30 Slofedipine xl 60 Tensipine mr 10 Tensipine mr 20 Unipine xl Valni 20 ret Valni xl Vasad
Status:	Approved (1981)
Entry Type:	Small molecule
Molecule Category:	Parent
ATC:	C08CA05
UNII:	I9ZF7L6G2L


InChI Key	HYIMSNHJOBLJNT-UHFFFAOYSA-N
Smile	COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1c1ccccc1[N+](=O)[O-]
InChI	InChI=1S/C17H18N2O6/c1-9-13(16(20)24-3)15(14(10(2)18-9)17(21)25-4)11-7-5-6-8-12(11)19(22)23/h5-8,15,18H,1-4H3

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C17H18N2O6
Molecular Weight	346.34
AlogP	2.18
Hydrogen Bond Acceptor	7.0
Hydrogen Bond Donor	1.0
Number of Rotational Bond	4.0
Polar Surface Area	107.77
Molecular species	NEUTRAL
Aromatic Rings	1.0
Heavy Atoms	25.0

Action	Mechanism of Action	Reference
BLOCKER	Voltage-gated L-type calcium channel blocker	Wikipedia Wikipedia Wikipedia Wikipedia FDA

Targets	EC50(nM)	IC50(nM)	Kd(nM)	Ki(nM)	Inhibition(%)
Auxiliary transport protein Calcium channel auxiliary subunit alpha2delta family	-	-	-	-	32-73
Auxiliary transport protein Calcium channel auxiliary subunit beta family	-	-	-	-	32-73
Auxiliary transport protein Calcium channel auxiliary subunit gamma family	-	-	-	-	32-73
Enzyme Cytochrome P450 Cytochrome P450 family 1 Cytochrome P450 family 1A Cytochrome P450 1A2	-	2300	-	-	-
Enzyme Cytochrome P450 Cytochrome P450 family 2 Cytochrome P450 family 2C Cytochrome P450 2C19	-	5420	-	-	-
Enzyme Cytochrome P450 Cytochrome P450 family 2 Cytochrome P450 family 2C Cytochrome P450 2C9	-	4080	-	-	-
Enzyme Cytochrome P450 Cytochrome P450 family 3 Cytochrome P450 family 3A Cytochrome P450 3A4	-	5620-46989	-	-	88
Enzyme Hydrolase	-	-	-	1200-5012	-
Enzyme Kinase Protein Kinase CAMK protein kinase group CAMK protein kinase MLCK family	-	2020	-	-	-
Enzyme Oxidoreductase	-	1500	-	17400	0
Enzyme	-	5620-46989	-	1200-5012	0
Ion channel Voltage-gated ion channel Potassium channels Two-pore domain potassium channel	-	8200	-	-	-
Ion channel Voltage-gated ion channel Potassium channels Voltage-gated potassium channel	-	50119-50119	-	-	-
Ion channel Voltage-gated ion channel Transient receptor potential channel	400	-	-	-	-
Ion channel Voltage-gated ion channel Voltage-gated calcium channel	12	2-58	0	15-15	0-100
Ion channel Voltage-gated ion channel Voltage-gated sodium channel	-	37000	-	-	26
Membrane receptor Family A G protein-coupled receptor Small molecule receptor (family A GPCR) Nucleotide-like receptor (family A GPCR) Adenosine receptor	-	-	-	22200-22200	-
Transporter Electrochemical transporter SLC superfamily of solute carriers SLC21/SLCO family of organic anion transporting polypeptides	-	-	-	-	-21-171
Transporter Primary active transporter ATP-binding cassette ABCB subfamily	-	18650-69000	-	-	-
Transporter Primary active transporter ATP-binding cassette ABCC subfamily	-	16600	-	-	-

Mesh Heading	Maximum Phase	Mesh ID	Reference
Kidney Calculi	3	D007669	ClinicalTrials
Diabetic Nephropathies	3	D003928	ClinicalTrials
Raynaud Disease	3	D011928	ClinicalTrials
Myocardial Ischemia	3	D017202	ClinicalTrials
Placenta Previa	3	D010923	ClinicalTrials
Premature Birth	3	D047928	ClinicalTrials
Hypertension, Pulmonary	3	D006976	ClinicalTrials
Anus Diseases	2	D001004	ClinicalTrials
Renal Insufficiency, Chronic	2	D051436	ClinicalTrials
Proteinuria	2	D011507	ClinicalTrials
Epilepsies, Partial	2	D004828	ClinicalTrials
Fissure in Ano	2	D005401	ClinicalTrials
Adrenal Hyperplasia, Congenital	1	D000312	ClinicalTrials
Substance-Related Disorders	1	D019966	ClinicalTrials

MCS

Target Level :

Level 3

Level 4

Level 5

Level 6

Extend :

Indication

Mechanism of Action

Primary Target

Target Level

Scaffolds

Target Level :

Level 3

Level 4

Level 5

Level 6

Extend network:

Indication

Mechanism of Action

Primary Target

Target Level

Side Effects from Label

Side Effects (PT)

Side effects	Relative Frequency (%)	Labels
Cardiac disorders Dizziness	27.0
General disorders and administration site conditions Feeling hot	25.0
General disorders and administration site conditions Flushing	25.0
Nervous system disorders Headache	23.0
Nervous system disorders Headache
Nervous system disorders Headache	19.0
Nervous system disorders Headache	16.6
Nervous system disorders Headache	15.8
Cardiac disorders Dizziness
Nervous system disorders Headache
General disorders and administration site conditions Asthenia	12.0
Gastrointestinal disorders Dyspepsia	11.0
Gastrointestinal disorders Nausea	11.0
General disorders and administration site conditions Oedema	10.1
General disorders and administration site conditions Asthenia
General disorders and administration site conditions Oedema	9.9
Nervous system disorders Headache
Gastrointestinal disorders Dyspepsia
General disorders and administration site conditions Feeling hot
General disorders and administration site conditions Flushing
Musculoskeletal and connective tissue disorders Muscle spasms	8.0
Respiratory, thoracic and mediastinal disorders Nasal congestion
Gastrointestinal disorders Nausea
Gastrointestinal disorders Oropharyngeal discomfort
Gastrointestinal disorders Oropharyngeal pain
Nervous system disorders Tremor	8.0
Psychiatric disorders Affect lability	7.0
Psychiatric disorders Mood swings	7.0
Psychiatric disorders Nervousness	7.0
Cardiac disorders Oedema peripheral	7.0
Cardiac disorders Palpitations	7.0
Psychiatric disorders Tension	7.0
General disorders and administration site conditions Asthenia	6.2
General disorders and administration site conditions Fatigue	6.2
Respiratory, thoracic and mediastinal disorders Cough	6.0
Cardiac disorders Dyspnoea	6.0
Respiratory, thoracic and mediastinal disorders Nasal congestion	6.0
Gastrointestinal disorders Oropharyngeal discomfort	6.0
Gastrointestinal disorders Oropharyngeal pain	6.0
Respiratory, thoracic and mediastinal disorders Wheezing	6.0
General disorders and administration site conditions Asthenia	5.9
General disorders and administration site conditions Fatigue	5.9
Cardiac disorders Palpitations
Cardiac disorders Dizziness
Cardiac disorders Dizziness	4.4
General disorders and administration site conditions Asthenia
Cardiac disorders Dizziness	4.1
General disorders and administration site conditions Fatigue
Psychiatric disorders Affect lability
General disorders and administration site conditions Asthenia
General disorders and administration site conditions Asthenia	4.0
Cardiac disorders Dizziness	4.0
General disorders and administration site conditions Fatigue
General disorders and administration site conditions Fatigue	4.0
General disorders and administration site conditions Feeling hot	4.0
General disorders and administration site conditions Flushing	4.0
Psychiatric disorders Mood swings
Psychiatric disorders Nervousness
Psychiatric disorders Tension
Nervous system disorders Headache	3.9
Gastrointestinal disorders Constipation	3.5
Gastrointestinal disorders Nausea	3.5
Gastrointestinal disorders Constipation	3.3
Gastrointestinal disorders Nausea	3.3
Cardiac disorders Angina pectoris	3.1
Nervous system disorders Headache	3.1
Respiratory, thoracic and mediastinal disorders Cough
Cardiac disorders Dyspnoea
Musculoskeletal and connective tissue disorders Muscle spasms
Nervous system disorders Tremor
Respiratory, thoracic and mediastinal disorders Wheezing
Musculoskeletal and connective tissue disorders Muscle spasms	2.7
General disorders and administration site conditions Pain	2.7
General disorders and administration site conditions Flushing	2.4
Gastrointestinal disorders Constipation
Skin and subcutaneous tissue disorders Dermatitis	2.3
Cardiac disorders Dizziness	2.3
Cardiac disorders Palpitations	2.3
Skin and subcutaneous tissue disorders Rash	2.3
General disorders and administration site conditions Asthenia	2.0
Cardiac disorders Dizziness
Gastrointestinal disorders Nausea	2.0
Gastrointestinal disorders Constipation	1.9
Gastrointestinal disorders Nausea
Nervous system disorders Insomnia	1.8
Psychiatric disorders Nervousness	1.8
Psychiatric disorders Tension	1.8
Cardiac disorders Dyspnoea	1.7
Gastrointestinal disorders Dyspepsia	1.5
Psychiatric disorders Erectile dysfunction	1.5
Gastrointestinal disorders Flatulence	1.5
Renal and urinary disorders Polyuria	1.5
Nervous system disorders Somnolence	1.5
Investigations Urine output increased	1.5
Gastrointestinal disorders Abdominal pain	1.4
Gastrointestinal disorders Gastrointestinal pain	1.4
Gastrointestinal disorders Abdominal pain	1.2
General disorders and administration site conditions Asthenia	1.2
Gastrointestinal disorders Dyspepsia	1.2
General disorders and administration site conditions Fatigue	1.2
Gastrointestinal disorders Gastrointestinal pain	1.2
Nervous system disorders Hypoaesthesia	1.2
Cardiac disorders Tachycardia	1.2
Cardiac disorders Chest pain	1.1
Gastrointestinal disorders Dry mouth	1.1
Skin and subcutaneous tissue disorders Pruritus	1.1
Gastrointestinal disorders Constipation	1.0
Gastrointestinal disorders Nausea
Cardiac disorders Oedema peripheral

Adverse Reactions

SOC By Demographic Distribution

System Organ Classification (SOC)

	Relative Frequency (%)
General disorders and administration site conditions	13.54
Injury, poisoning and procedural complications	11.22
Pregnancy, puerperium and perinatal conditions	10.16
Cardiac disorders	8.6
Vascular disorders	8.23
Nervous system disorders	7.98
Immune system disorders	5.2
Respiratory, thoracic and mediastinal disorders	5.01
Gastrointestinal disorders	4.31
Investigations	4.04
Psychiatric disorders	3.92
Skin and subcutaneous tissue disorders	3.79
Musculoskeletal and connective tissue disorders	2.62
Metabolism and nutrition disorders	2.48
Renal and urinary disorders	2.13

Cross References

Resources	Reference
CAS NUMBER	21829-25-4
ChEBI	7565
ChEMBL	CHEMBL193
DrugBank	DB01115
DrugCentral	1922
EPA CompTox	DTXSID2025715
FDA SRS	I9ZF7L6G2L
Human Metabolome Database	HMDB0015247
Guide to Pharmacology	2514
KEGG	C07266
PDB	C5U
PharmGKB	PA450631
PubChem	4485
SureChEMBL	SCHEMBL3968
ZINC	ZINC000085205448

NIFEDIPINE

Structure

Physicochemical Descriptors

Pharmacology

Metabolites

Indications

Related Entries

MCS

Scaffolds

Side Effects from Label

Adverse Reactions

Cross References


Active Pharmaceutical Ingredients (APIs) Scaffolds	Exact Similarity SubStructure	Threshold (%) >= 70